United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 38-3317208 (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from to Commission file number 000-23661 ROCKWELL MEDICAL, INC. FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q3 2021 Earnings Conference Call November 15, 2021 4:00 PM ET Company Participants Jason Finkelstein - SVP, Argot Partners, IR Russell Ellison - President & CEO Russell Skibsted - EVP, CFO & Chief Business Officer Marc Hoffman - Chief Medical Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical Third Quarter 2021 Results Conference Call. As a reminder, this conference ...

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 38-3317208 (State or other jur ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q2 2021 Earnings Conference Call August 16, 2021 4:30 PM ET Company Participants Jason Finkelstein - Investor Relations, Argot Partners Russell Ellison - President & Chief Executive Officer Russell Skibsted - Executive Vice President, Chief Financial Officer & Chief Business Officer Marc Hoffman - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good afternoon ladies and gentlemen, and welcome to the Rockwell Medical Q2 2021 ...

Financial Performance - Net sales for the three months ended June 30, 2021, were $15.137 million, a decrease of 4.8% compared to $15.896 million for the same period in 2020[12] - The company reported a net loss of $8.400 million for the three months ended June 30, 2021, compared to a net loss of $6.892 million for the same period in 2020, indicating an increase in losses of approximately 22%[12] - Gross profit for the six months ended June 30, 2021, was $140, compared to $1.994 million for the same period in 2020, indicating a significant decline in profitability[12] - Basic and diluted net loss per share for the three months ended June 30, 2021, was $0.09, compared to $0.10 for the same period in 2020[12] - The company reported a comprehensive loss of $16,157,000 for the first half of 2021, compared to $14,882,000 for the same period in 2020[14] - The company reported a net loss of $16.15 million for 2021, compared to a net loss of $14.88 million in 2020, indicating a year-over-year increase in losses of approximately 8.5%[22] Assets and Liabilities - Total assets decreased from $77.748 million as of December 31, 2020, to $63.684 million as of June 30, 2021, representing a decline of approximately 18%[10] - Total current liabilities rose significantly from $12.793 million as of December 31, 2020, to $34.038 million as of June 30, 2021, marking an increase of approximately 166%[10] - The company’s accumulated deficit increased from $337.406 million as of December 31, 2020, to $353.558 million as of June 30, 2021, representing a deterioration of about 4.8%[10] - As of June 30, 2021, the accumulated deficit was approximately $353.6 million, with stockholders' equity of $18.2 million[27] - The company had approximately $41 million in cash, cash equivalents, and investments available-for-sale as of June 30, 2021[27] Research and Development - Research and product development expenses increased to $2.416 million for the three months ended June 30, 2021, up from $1.616 million in the same period of 2020, reflecting a rise of 49.5%[12] - The company plans to advance its ferric pyrophosphate citrate (FPC) platform strategy outside of dialysis with a Phase II trial for iron deficiency anemia in 2021[25] Revenue Recognition and Agreements - The company recognizes revenue based on the transfer of control of products, with payment terms averaging 30 days for customers and 45 days for distributors[52] - The company recognized $9.1 million in revenue expected to be recognized in future years related to remaining performance obligations as of June 30, 2021, primarily from upfront payments[61] - The Baxter Agreement includes unfulfilled minimum commitments of product sales amounting to $6.2 million as of June 30, 2021, to be amortized through October 2, 2024[61] - The company recognized approximately $0.5 million and $1.0 million in revenue from the Baxter Agreement for the three and six months ended June 30, 2021, respectively[69] Stock-Based Compensation - The Company recognized total stock-based compensation expense of $433,000 for the three months ended June 30, 2021, compared to a negative expense of $1,461,000 for the same period in 2020[85] - The company recognized stock-based compensation expense of $0.1 million for the three months ended June 30, 2021, and $0.2 million for the six months ended June 30, 2021[88] - As of June 30, 2021, total unrecognized stock-based compensation expense related to unvested options was approximately $2.0 million, expected to be recognized over an estimated average term of 3.0 years[93] Operational Challenges - The COVID-19 pandemic has adversely affected the company's sales and marketing efforts, as well as research and development activities[32] - The company expects to require additional capital to sustain operations and execute its strategic plan, including the commercialization of Triferic and Triferic AVNU[29] - The company has utilized various financing methods to fund operations, but current market conditions may limit funding availability[33]

| --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | Q1 2021 Financial Results and Business Update ROCKWELL MEDICAL, INC. TRANSFORMING IRON DEFICIENCY AND ANEMIA MANAGEMENT | | | | | | | | | May 17, 2021 | | | | | | | | FORWARD-LOOKING STATEMENTS 2 Certain statements in this presentation may constitute "forward-l ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q1 2021 Earnings Conference Call May 17, 2021 4:30 PM ET Company Participants Claudia Styslinger - Investor Relations Russell Ellison - President and Chief Executive Officer Russell Skibsted - EVP, Chief Financial Officer and Chief Business Officer Marc Hoffman - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Thank you for standing by and welcome to the Rockwell Medical First Quarter 2021 Results Call. At this time all part ...

United States SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Form 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-23661 ROCKWELL MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 38-3317208 (State or other jurisdi ...

Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2020 Earnings Conference Call March 31, 2021 4:30 PM ET Company Participants Claudia Styslinger - IR, Argo Partners Russell Ellison - President and CEO Tim Chole - VP, Marketing Marc Hoffman - CMO Russell Skibsted - EVP, CFO and Chief Business Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald Operator Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical Fourth Quarter and Full Year 2020 Results Call. At this time all particip ...